Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.
Shares float: 61.87M
Topline Data 16/10/2024 ET
Phase 2 topline data to be presented at ISPAD October 16-19, 2024. Phase 2 first patient dosed April 13, 2023. Phase 2 enrollment completed, noted February 8, 2024. Phase 2 data demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression, noted April 10, 2024.
2 more catalysts end of August 2025 and end of December 2025
Huge down gap from $18.00 to $4.50
Breakout and Entry Zone above: $2.60
Action: If the stock breaks above this area with strong volume, it might signal a continuation of the upward trend.
Overall Market Sentiment: Currently, the market seems to be in a correction phase. It’s crucial to consider this sentiment when making trading decisions.
Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.
Trading Strategy:
Take Profit (TP): Set a target at $6.50 (pre catalyst run up) and if we see a full gap fill set a second one at $18.00 (highly speculative and could take time)
Stop Loss (SL): Set at under $1.70 to mitigate potential losses.
Chart Analysis: Please refer to the attached chart for detailed analysis of price trends and movements.
Trading Advisory: Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.
Disclaimer: This content is for informational purposes only and should not be considered financial advice.
Ghi chú
slow and steady - let's gooo
Ghi chú
Amylyx Pharmaceuticals Shares Jump After Wolfram Syndrome Treatment Study Shows Improvement
Oct 17, 2024
Amylyx Pharmaceuticals Price Target Maintained With a 8.00/Share by HC Wainwright & Co.
Oct 18, 2024
boooom!
Giao dịch đang hoạt động
its slowly pushing higher
recent passive stakes:
25/10/2024
Amylyx Pharmaceuticals, Inc. Passive Stake (FormSC13G) by PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD
4/11/2024
Amylyx Pharmaceuticals, Inc. Passive Stake (FormSC13G) by The Vanguard Group
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.